<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02175147</url>
  </required_header>
  <id_info>
    <org_study_id>305555</org_study_id>
    <nct_id>NCT02175147</nct_id>
  </id_info>
  <brief_title>Patient-centred Integrated Palliative Care Pathways in Advanced Cancer and Chronic Disease</brief_title>
  <acronym>InSup-C</acronym>
  <official_title>Patient-centred Integrated Palliative Care Pathways in Advanced Cancer and Chronic Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>European Union</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medical University of Pecs</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Lancaster General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Bonn</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Katholieke Universiteit Leuven</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>World Health Organization</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>European Association for Palliative Care</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Rotterdam, The Netherlands</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Navarra</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Sheffield</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Icahn School of Medicine at Mount Sinai</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Radboud University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rationale: Palliative care integration in treatment pathways, palliative care networks and
      institutional collaborations in health services delivery seems a promising approach reducing
      fragmentation and discontinuity. Integrated Palliative Care (IPC) approaches in Europe are
      largely unknown and under-investigated. The investigators aim is to explore experiences of
      patients with advanced cancer, Chronic Obstructive Pulmonary Disease (COPD) and Chronic Heart
      Failure (CHF), family and professional caregivers within with IPC. This includes perceived
      quality of life, quality of care, burden/rewards of care giving, symptoms and collaboration
      between caregivers in the patient's care network.

      Objectives: To investigate how patients with advanced cancer, COPD and CHF, their family and
      professional caregivers within a selection of IPC initiatives in Belgium, Germany, Hungary,
      The Netherlands and United Kingdom experience care delivery in the last phase of disease.

        -  To investigate what opinions patients and family caregivers have on the (continuity and)
           quality of care delivered

        -  To investigate how patients rate their symptoms and quality of life

        -  To investigate how family caregivers rate their burden / rewards of care giving

        -  To investigate how the care network of the patient is organised with respect to the
           type, properties and quality of relationships between patients and family / professional
           caregivers

      Study design: Longitudinal multiple embedded case study.

      Study population: Adult patients with advanced cancer, COPD, and CHF under the care of IPC
      initiatives in five participating countries, their family and professional caregivers. The
      investigators aim to enroll up to 288 patients, 288 family caregivers and 192 professional
      caregivers in total.

      Study parameters: Experiences with IPC initiatives, quality of care, quality of life,
      perceived symptoms, perceived collaboration between professional caregivers, burden and
      rewards of care giving.

      Methods: Semi-structured interviews, patient diary, Social Network Analysis and the following
      questionnaires: Palliative care Outcome Scale; Canhelp Lite, Caregiver Reaction Assessment.
      Patients and family caregivers will be followed over 3 months at 4 consecutive contact
      points. The diary (containing two questions) will be kept weekly by patients. There will be
      group or individual interviews with professional caregivers.

      Analysis: The overall analysis will involve a synthesis of the qualitative and quantitative
      data. For more information see Detailed Description.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Monitoring and Quality Assurance:

      Training for researchers:

      In order to ensure the best quality of the study, researchers will take part in at least two
      compulsory training sessions. During the training ethical and professional issues will also
      be discussed, such as:

        -  ethical issues (e.g. handling vulnerable groups in interview situations)

        -  data management (protection of privacy of medical and research records)

        -  interview training in order to standardise interview techniques

        -  how to analyse qualitative and quantitative data, and how to synthesize them in this
           research (to the analysing researchers in the partner countries).

      Qualitative data:

      Interviews will be tape recorded and transcribed verbatim, and will be evaluated with content
      analysis using qualitative software package NVivo 10. After two pilot interviews responsible
      researchers from each partner country will discuss a preliminary code book. These codes and
      themes will form the basis of the coding strategy throughout data collection and the data
      analysis. Analysis will be ongoing throughout the fieldwork in order to allow emergent themes
      to be fed back into the data collection. During data collection new relevant codes will be
      included in the code book.

      The interviews will be coded in the national languages of the five countries under
      examination. This will result in five country reports about the experiences of patients with
      advanced cancer, COPD and CHF, their family and professional caregivers within a selection of
      IPC initiatives in the particular country with the care delivery in the last phase of
      disease. These country reports will be translated into English and will be analysed and
      result in one overall report.

      Quantitative data:

      Statistical analysis will be performed using SPSS Statistics 20. The investigators will use
      descriptive statistics such as frequencies, crosstabs, means, standard deviation. The
      quantitative data will be used as a background description of the population. The overall
      analysis will involve a synthesis of the qualitative and quantitative data. During the
      analysis phase the investigators will integrate the quantitative variables, qualitative
      findings and evaluations in order to get complete insight in the topic.

      Treatments for missing data:

      The investigators will use the following approach to missing data: to omit questions with
      missing data and to perform analyses of questions on what remains. Missing data will be
      accounted for in the analysis and the implications will be made clear.

      Handling and storage of data and documents:

      The confidentiality of data collected within the patient study will be secured according to
      national and European regulation. Data from patients will be anonymised and disclosure of
      information from the study to third parties will be limited to those undertaking legitimate
      peer review of the scientific and ethical aspects of the study, co-workers and patients, so
      that consent can be obtained and customary medical care can be provided.

      Patient confidentiality and welfare will always be maintained as the highest priority. All
      data gathered and documents will be stored anonymously. Each patient, family caregiver and
      professional caregiver will be allocated a unique identification number. No identifying
      information linking the person and identification number will be kept on the data base. The
      investigators will analyze data by identification number only. Patient data will be stored in
      a protected database with log function. The master database will be kept at the centre of the
      research coordinator of the Radboud University Medical Centre.

      Assessment of progress and quality:

      Researchers (who will do fieldwork at IPC initiatives involved) will report fieldwork
      progress (patient recruitment and data collection) and the quality of data collected every
      other week to their lead researcher (who is responsible for the research in the particular
      country). Contents of the progress and quality report:

        1. Number of persons (patients and family caregivers) involved

        2. Number of completed questionnaires and interviews

        3. Quality of completed questionnaires and interviews

        4. Attrition (death of patients, early terminated interviews)

        5. Other research-related events (e.g. delays)

      Lead researchers will summarize researches' reports and send a progress and quality report to
      the study principal investigator every month (The study principal investigator is responsible
      for the research in the framework of InSup-C project.)

      The study principal investigator organizes a 3‚Äêmonthly structure of (tele)conference to
      monitor progress and quality and to report this to the Project Management Office (PMO). The
      PMO works under supervision of the Executive Board of the project. The PMO will provide the
      Executive Board with project process reports at least every six months or more frequently if
      necessary.

      Annual progress report:

      The Principal Investigator will submit a summary of the progress of the study to the
      accredited ethical committee once a year. Information will be provided on the date of
      inclusion of the first subject, numbers of subjects included and numbers of subjects that
      have completed the trial, (serious) adverse events, other problems, and amendments.

      End of study report:

      The Principal Investigator will notify the accredited ethical committee of the end of the
      study within a period of eight weeks. The end of the study is defined as the last study
      participant's last interview. In case the study is ended prematurely, the responsible
      researcher will notify the accredited ethical committee within 15 days, including the reasons
      for the premature termination.

      Within one year after the end of the study, the responsible researcher will submit a final
      study report with the results of the study, including any publications/abstracts of the
      study, to the accredited ethical committee.

      Public disclosure and publication policy:

      Public disclosure and publication policy is regulated by InSup-C. Dissemination Strategy
      (October 2013), available at request. An outline publication timeline with suggested topics,
      lead work package author and scientific target journals is detailed in the Dissemination
      Strategy. An interactive website has been developed. The website will signpost study results
      as these become available.

      Monitoring level related to risk classification:

      As in the previous section it was estimated that this study has a negligible risk, minimal
      monitoring will take place. Table 4 displays the activities the monitor will perform.
      Monitoring will be conducted by a qualified monitor who has knowledge of current legislation
      and regulation and who is independent from this study. Findings will be reported to the
      coordinating investigator of the Radboud umc in a fixed format. If the monitor identifies
      substantial and/or frequent faults, this will be reported to the head of the department
      and/or the company board.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2014</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>3 Months</target_duration>
  <primary_outcome>
    <measure>Change from baseline Experiences with IPC initiatives at 3 months</measure>
    <time_frame>Baseline and Month 3</time_frame>
    <description>The semi-structured interviews will be used to explore views of patients and family caregivers about their experiences with the integrated palliative care initiative. Topics include:
An exploration of problems and needs of the patient
An exploration of the contacts and relationships of patients and family caregivers with professional caregivers
An exploration of satisfaction and perceived deficits in service provision from the perspective of patients and family caregivers
An exploration of the views of patients and family caregivers on collaboration between professional care providers in the care network of the patient.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline Quality of care at 1, 2 and 3 months</measure>
    <time_frame>Baseline, Month 1, Month 2, Month 3</time_frame>
    <description>Quality of care/satisfaction will be measured using the Canhelp Lite and the Social Network Analysis (SNA) method.
Outcomes will be explored in the interviews, see also &quot;Experiences with IPC initiatives&quot;</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline Quality of life at 1, 2, and 3 months</measure>
    <time_frame>Baseline, Month 1, Month 2, Month 3</time_frame>
    <description>Quality of Life will be measured using the Palliative Care Outcome Scale (POS) version 1.
Outcomes will be explored in the interviews, see also &quot;Experiences with IPC initiatives&quot;</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline Perceived symptoms at 1, 2, and 3 months</measure>
    <time_frame>Baseline, Month 1, Month 2, Month 3</time_frame>
    <description>Quality of Life will be measured using the Palliative Care Outcome Scale (POS) version 1.
Outcomes will be explored in the interviews, see also &quot;Experiences with IPC initiatives&quot;.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from Perceived collaboration between professional caregivers at 3 months</measure>
    <time_frame>Baseline, Month 3</time_frame>
    <description>Quality of Life will be measured using Social Network Analysis method (SNA). Outcomes will be explored in the interviews, see also &quot;Experiences with IPC initiatives&quot;</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline Burden and rewards of care giving at 1, 2, and 3 months</measure>
    <time_frame>Baseline, Month 1, Month 2, Month 3</time_frame>
    <description>Burden and rewards of care giving will be measured using the Caregiver Reaction Assessment.</description>
  </primary_outcome>
  <enrollment type="Anticipated">576</enrollment>
  <condition>COPD</condition>
  <condition>Cancer</condition>
  <condition>Heart Failure</condition>
  <eligibility>
    <study_pop>
      <textblock>
        In Belgium, Germany, Hungary, The Netherlands and United Kingdom 3-5 'model initiatives' of
        palliative care were selected. From each initiative, patients with advanced cancer, COPD
        and CHF, their family and professional caregivers are recruited. Patients (and if presented
        the family caregiver) are recruited by their main responsible doctor or (research) nurse
        involved in the initiative under examination. Participants need to meet the inclusion and
        exclusion criteria in order to be eligible for the study. A family caregiver is defined as
        the person who takes care and supports the patient for most of the time. Family caregivers
        are not necessarily a family member. Professional caregivers involved in the IPC
        initiatives under examination are invited for the group interviews.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Aged 18 year or above

          2. Able to communicate in the national language (Dutch, English, German, Hungarian)

          3. Cognitively able to complete questionnaires and to participate in interviews.

             Additional inclusion criteria for patients:

          4. Surprise question &quot;Would the patient's attending doctor be surprised if the patient
             died within 1 year?&quot; is answered &quot;No&quot; by the patient's attending doctor

          5. Patients need to meet on of the following clinical criteria:

               -  Malignant disease: Advanced cancer (cancer with local progression and / or
                  distant metastasis at presentation).

               -  Chronic Heart Failure: Severe heart failure (in accordance with New York Heart
                  Association (NYHA) classification stage III-IV)

               -  COPD: Gold stage IV classification

        Exclusion criteria:

        1. People who lack mental capacity to give interviews and fill in questionnaires
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marieke Groot, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Radboud University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marlieke van der Eerden, MSc.</last_name>
    <phone>+31243655606</phone>
    <email>Marlieke.vanderEerden@radboudumc.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marieke Groot, Dr.</last_name>
    <phone>+31243666252</phone>
    <email>Marieke.Groot@radboudumc.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Katholieke Universiteit Leuven</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Karen v Beek, MD, MSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Bonn</name>
      <address>
        <city>Bonn</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Benjamin Ewers, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical University of Pecs</name>
      <address>
        <city>Pecs</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Agnes Csikos, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Radboud University Medical Centre Palliative consultation team</name>
      <address>
        <city>Nijmegen</city>
        <state>Gelderland</state>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Marlieke vd Eerden, MSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lancaster General Hospital</name>
      <address>
        <city>Lancaster</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Sean Hughes, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Netherlands</country>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://www.insup-c.eu</url>
    <description>This is the website providing information about the InSup-C study</description>
  </link>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 2, 2014</study_first_submitted>
  <study_first_submitted_qc>June 25, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 26, 2014</study_first_posted>
  <last_update_submitted>June 25, 2014</last_update_submitted>
  <last_update_submitted_qc>June 25, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 26, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Chronic Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

